Severe cutaneous reaction to sorafenib: induction of tolerance.
Bauer
Carolyn
C
Przybilla
Bernhard
B
Ruëff
Franziska
F
D000368:Aged; D001557:Benzenesulfonates / Q000008:administration & dosage* / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004485:Eczema / Q000139:chemically induced*; D005260:Female; D006801:Humans; D020714:Maximum Tolerated Dose; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects*; D000077157:Sorafenib
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib